...
search icon
eypt-img

Eyepoint Pharmaceuticals Inc, Common Stock

EYPT

NMQ

$5.96

+$0.28

(4.93%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$427.32M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.45M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.60
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.91 L
$13.98 H
$5.96

About Eyepoint Pharmaceuticals Inc, Common Stock

EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameEYPTSectorS&P500
1-Week Return-4.03%-3.24%-2.29%
1-Month Return-12.09%-5.96%5.13%
3-Month Return-4.33%-11.47%-1.04%
6-Month Return-34.14%-11.3%-3.3%
1-Year Return-46.45%-8.64%9.3%
3-Year Return-38.49%-2.75%39.44%
5-Year Return-32.26%29.73%90.79%
10-Year Return-84.64%73.6%173.11%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue34.44M36.94M41.40M46.02M43.27M[{"date":"2020-12-31","value":74.83,"profit":true},{"date":"2021-12-31","value":80.27,"profit":true},{"date":"2022-12-31","value":89.97,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":94.03,"profit":true}]
Cost of Revenue5.82M8.18M8.33M4.63M3.71M[{"date":"2020-12-31","value":69.95,"profit":true},{"date":"2021-12-31","value":98.21,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":55.63,"profit":true},{"date":"2024-12-31","value":44.58,"profit":true}]
Gross Profit28.61M28.76M33.08M41.39M39.56M[{"date":"2020-12-31","value":69.14,"profit":true},{"date":"2021-12-31","value":69.5,"profit":true},{"date":"2022-12-31","value":79.93,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":95.59,"profit":true}]
Gross Margin83.09%77.86%79.89%89.93%91.42%[{"date":"2020-12-31","value":90.88,"profit":true},{"date":"2021-12-31","value":85.17,"profit":true},{"date":"2022-12-31","value":87.39,"profit":true},{"date":"2023-12-31","value":98.37,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses65.90M84.04M112.02M115.05M185.41M[{"date":"2020-12-31","value":35.54,"profit":true},{"date":"2021-12-31","value":45.32,"profit":true},{"date":"2022-12-31","value":60.41,"profit":true},{"date":"2023-12-31","value":62.05,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(37.29M)(55.28M)(78.94M)(75.07M)(145.85M)[{"date":"2020-12-31","value":-3729000000,"profit":false},{"date":"2021-12-31","value":-5527600000,"profit":false},{"date":"2022-12-31","value":-7893800000,"profit":false},{"date":"2023-12-31","value":-7506700000,"profit":false},{"date":"2024-12-31","value":-14585400000,"profit":false}]
Total Non-Operating Income/Expense(15.30M)(8.35M)(3.67M)10.06M30.15M[{"date":"2020-12-31","value":-50.76,"profit":false},{"date":"2021-12-31","value":-27.69,"profit":false},{"date":"2022-12-31","value":-12.19,"profit":false},{"date":"2023-12-31","value":33.36,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(45.39M)(58.42M)(102.25M)(70.71M)(130.78M)[{"date":"2020-12-31","value":-4539400000,"profit":false},{"date":"2021-12-31","value":-5841700000,"profit":false},{"date":"2022-12-31","value":-10225400000,"profit":false},{"date":"2023-12-31","value":-7071200000,"profit":false},{"date":"2024-12-31","value":-13078000000,"profit":false}]
Income Taxes7.26M5.50M22.26M83.00K90.00K[{"date":"2020-12-31","value":32.6,"profit":true},{"date":"2021-12-31","value":24.7,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":0.37,"profit":true},{"date":"2024-12-31","value":0.4,"profit":true}]
Income After Taxes(52.65M)(63.91M)(124.51M)(70.80M)(130.87M)[{"date":"2020-12-31","value":-5265100000,"profit":false},{"date":"2021-12-31","value":-6391500000,"profit":false},{"date":"2022-12-31","value":-12451200000,"profit":false},{"date":"2023-12-31","value":-7079500000,"profit":false},{"date":"2024-12-31","value":-13087000000,"profit":false}]
Income From Continuous Operations(45.39M)(58.42M)(102.25M)(70.80M)(130.87M)[{"date":"2020-12-31","value":-4539400000,"profit":false},{"date":"2021-12-31","value":-5841700000,"profit":false},{"date":"2022-12-31","value":-10225400000,"profit":false},{"date":"2023-12-31","value":-7079500000,"profit":false},{"date":"2024-12-31","value":-13087000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(52.65M)(63.91M)(124.51M)(70.80M)(130.87M)[{"date":"2020-12-31","value":-5265100000,"profit":false},{"date":"2021-12-31","value":-6391500000,"profit":false},{"date":"2022-12-31","value":-12451200000,"profit":false},{"date":"2023-12-31","value":-7079500000,"profit":false},{"date":"2024-12-31","value":-13087000000,"profit":false}]
EPS (Diluted)(3.40)(2.02)(2.73)(1.83)(2.31)[{"date":"2020-12-31","value":-340,"profit":false},{"date":"2021-12-31","value":-202,"profit":false},{"date":"2022-12-31","value":-273,"profit":false},{"date":"2023-12-31","value":-183,"profit":false},{"date":"2024-12-31","value":-231,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

EYPT
Cash Ratio 7.63
Current Ratio 7.85
Quick Ratio 7.79

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

EYPT
ROA (LTM) -29.16%
ROE (LTM) -53.54%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

EYPT
Debt Ratio Lower is generally better. Negative is bad. 0.18
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.82

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

EYPT
Trailing PE NM
Forward PE NM
P/S (TTM) 6.97
P/B 1.31
Price/FCF NM
EV/R 1.73
EV/Ebitda NM

FAQs

What is Eyepoint Pharmaceuticals Inc share price today?

Eyepoint Pharmaceuticals Inc (EYPT) share price today is $5.96

Can Indians buy Eyepoint Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Eyepoint Pharmaceuticals Inc (EYPT) on Vested. To buy Eyepoint Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EYPT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Eyepoint Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Eyepoint Pharmaceuticals Inc (EYPT) via the Vested app. You can start investing in Eyepoint Pharmaceuticals Inc (EYPT) with a minimum investment of $1.

How to invest in Eyepoint Pharmaceuticals Inc shares from India?

You can invest in shares of Eyepoint Pharmaceuticals Inc (EYPT) via Vested in three simple steps:

  • Click on Sign Up or Invest in EYPT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Eyepoint Pharmaceuticals Inc shares
What is Eyepoint Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Eyepoint Pharmaceuticals Inc (EYPT) is $13.98. The 52-week low price of Eyepoint Pharmaceuticals Inc (EYPT) is $3.91.

What is Eyepoint Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Eyepoint Pharmaceuticals Inc (EYPT) is 1.31

What is the Market Cap of Eyepoint Pharmaceuticals Inc?

The market capitalization of Eyepoint Pharmaceuticals Inc (EYPT) is $427.32M

What is Eyepoint Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Eyepoint Pharmaceuticals Inc is EYPT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top